<DOC>
	<DOCNO>NCT01968915</DOCNO>
	<brief_summary>This study evaluate safety tolerability estimate maximum tolerate dose and/or recommend dose oral LCL161 Japanese patient advance solid tumor .</brief_summary>
	<brief_title>Safety Tolerability Oral LCL161 Japanese Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients histologically cytologically confirm diagnosis solid tumor effective standard treatment available . 2 . ECOG performance status 01 . 3 . Patients must recover toxicity relate previous treatment . Exclusion criterion : 1 . Unresolved nausea , vomit , diarrhea peripheral neuropathy CTCAE grade &gt; 1 . 2 . History current interstitial lung disease autoimmune disease . 3 . History current impaired cardiac function clinically significant cardiac disease . 4 . Women childbearing potential , unless use highly effective method contraception . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>LCL161 , Paclitaxel , Japanese patient , Neoplasms</keyword>
</DOC>